4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Accumulated Expenses data on file, last reported at $6.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 10.38% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 10.38% increase from a year earlier, with the FY2025 full-year figure at $13.8 million, down 26.83% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.2 million, down from $13.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for FDMT reached as high as $24.2 million in Q3 2025 and fell as low as $2.9 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $9.2 million across 5 years, with a median of $6.2 million in 2026.
• Across the five-year window, Accumulated Expenses plunged 40.04% in 2022 and surged 249.29% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $5.7 million in 2022, then surged by 43.24% to $8.1 million in 2023, then surged by 131.55% to $18.9 million in 2024, then retreated by 26.83% to $13.8 million in 2025, then plunged by 54.77% to $6.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $6.2 million in Q1 2026, $13.8 million in Q4 2025, and $24.2 million in Q3 2025.